Video Upload Options

References

1. Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE, Perroni L,Dagna-Bricarelli F, Sartirana C, Matthes-Martin S, Lawitschka A, Azzari C,Ziegler SF, Levings MK, Roncarolo MG. Defective regulatory and effector T cellfunctions in patients with FOXP3 mutations. J Clin Invest. 2006Jun;116(6):1713-22.
2. Bin Dhuban K, Piccirillo CA. The immunological and genetic basis of immunedysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Curr OpinAllergy Clin Immunol. 2015 Dec;15(6):525-32. doi: 10.1097/ACI.0000000000000214.Review.
3. Fuchizawa T, Adachi Y, Ito Y, Higashiyama H, Kanegane H, Futatani T, KobayashiI, Kamachi Y, Sakamoto T, Tsuge I, Tanaka H, Banham AH, Ochs HD, Miyawaki T.Developmental changes of FOXP3-expressing CD4+CD25+ regulatory T cells and their impairment in patients with FOXP3 gene mutations. Clin Immunol. 2007Dec;125(3):237-46.
4. Nik Tavakoli N, Hambly BD, Sullivan DR, Bao S. Forkhead box protein 3:essential immune regulatory role. Int J Biochem Cell Biol. 2008;40(11):2369-73.
5. Otsubo K, Kanegane H, Kamachi Y, Kobayashi I, Tsuge I, Imaizumi M, Sasahara Y,Hayakawa A, Nozu K, Iijima K, Ito S, Horikawa R, Nagai Y, Takatsu K, Mori H, OchsHD, Miyawaki T. Identification of FOXP3-negative regulatory T-like(CD4(+)CD25(+)CD127(low)) cells in patients with immune dysregulation,polyendocrinopathy, enteropathy, X-linked syndrome. Clin Immunol. 2011Oct;141(1):111-20. doi: 10.1016/j.clim.2011.06.006.
6. Tan QKG, Louie RJ, Sleasman JW. IPEX Syndrome. 2004 Oct 19 [updated 2018 Jul19]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K,Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University ofWashington, Seattle; 1993-2020. Available fromhttp://www.ncbi.nlm.nih.gov/books/NBK1118/
7. Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. JAllergy Clin Immunol. 2007 Oct;120(4):744-50; quiz 751-2. Review.